{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:38:25Z","timestamp":1792852705955,"version":"4.5.0"},"reference-count":78,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,1,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Anticoagulant therapy is often refrained from out of fear of hemorrhagic complications. The most frequent type of major bleeding is gastrointestinal, but intracranial hemorrhage has the worst prognosis. Management of these complications in patients on anticoagulants should follow the same routines as for nonanticoagulated patients, as described here with the previously mentioned bleeds as examples. In addition, for life-threatening or massive hemorrhages, reversal of the anticoagulant effect is also crucial. Adequate reversal requires information on which anticoagulant the patient has taken and when the last dose was ingested. Laboratory data can be of some help, but not for all anticoagulants in the emergency setting. This is reviewed here for the different types of anticoagulants: vitamin K antagonists, heparins, fondaparinux, thrombin inhibitors and factor Xa inhibitors. Specific antidotes for the latter are becoming available, but supportive care and nonspecific support for hemostasis with antifibrinolytic agents or prothrombin complex concentrates, which are widely available, should be kept in mind.<\/jats:p>","DOI":"10.1182\/blood-2018-06-820746","type":"journal-article","created":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T20:35:45Z","timestamp":1545078945000},"page":"425-435","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":103,"title":["Treatment of bleeding complications in patients on anticoagulant therapy"],"prefix":"10.1182","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5052-9418","authenticated-orcid":false,"given":"Siavash","family":"Piran","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology and Thromboembolism, and Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8512-9043","authenticated-orcid":false,"given":"Sam","family":"Schulman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Thromboembolism, and Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Canada; and"},{"name":"Department of Obstetrics and Gynecology, The First I.M. Sechenov Moscow State Medical University, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6 suppl","key":"2020021109334868300_B1","doi-asserted-by":"crossref","first-page":"257S","DOI":"10.1378\/chest.08-0674","article-title":"Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Schulman","year":"2008","journal-title":"Chest"},{"issue":"1","key":"2020021109334868300_B2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/STROKEAHA.107.495036","article-title":"Barriers to the use of anticoagulation for nonvalvular atrial fibrillation: a representative survey of Australian family physicians [published corrections appear in Stroke. 2008;39(1):227-230; and Stroke. 2010;41:e398]","volume":"39","author":"Gattellari","year":"2008","journal-title":"Stroke"},{"issue":"10","key":"2020021109334868300_B3","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1001\/archinte.1991.00400100032005","article-title":"The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial","volume":"151","author":"Lancaster","year":"1991","journal-title":"Arch Intern Med"},{"issue":"10","key":"2020021109334868300_B4","doi-asserted-by":"crossref","first-page":"789","DOI":"10.7326\/0003-4819-130-10-199905180-00002","article-title":"Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis","volume":"130","author":"Gould","year":"1999","journal-title":"Ann Intern Med"},{"issue":"4","key":"2020021109334868300_B5","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.thromres.2015.07.030","article-title":"Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists","volume":"136","author":"De Crem","year":"2015","journal-title":"Thromb Res"},{"issue":"10","key":"2020021109334868300_B6","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1016\/S2352-3026(16)30111-9","article-title":"Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series","volume":"3","author":"Beyer-Westendorf","year":"2016","journal-title":"Lancet Haematol"},{"issue":"11","key":"2020021109334868300_B7","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2015-08-665927","article-title":"Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use","volume":"127","author":"Martinelli","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2020021109334868300_B8","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2020021109334868300_B9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.CIR.76.1.142","article-title":"Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge","volume":"76","author":"Chesebro","year":"1987","journal-title":"Circulation"},{"issue":"4","key":"2020021109334868300_B10","doi-asserted-by":"crossref","first-page":"256","DOI":"10.7326\/0003-4819-115-4-256","article-title":"Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial","volume":"115","author":"Bovill","year":"1991","journal-title":"Ann Intern Med"},{"issue":"11","key":"2020021109334868300_B11","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"2020021109334868300_B12","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/clpt.2013.99","article-title":"Bleeding risk in atrial fibrillation patients taking vitamin K antagonists: systematic review and meta-analysis","volume":"94","author":"Lopes","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"15","key":"2020021109334868300_B13","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood-2014-07-590323","article-title":"The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis","volume":"124","author":"Chai-Adisaksopha","year":"2014","journal-title":"Blood"},{"key":"2020021109334868300_B14","doi-asserted-by":"crossref","first-page":"i3189","DOI":"10.1136\/bmj.i3189","article-title":"Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study","volume":"353","author":"Larsen","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"2020021109334868300_B15","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/STROKEAHA.117.018395","article-title":"Real-world use of apixaban for stroke prevention in atrial fibrillation: a systematic review and meta-analysis","volume":"49","author":"Proietti","year":"2018","journal-title":"Stroke"},{"issue":"2","key":"2020021109334868300_B16","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"issue":"18","key":"2020021109334868300_B17","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa035451","article-title":"Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism","volume":"349","author":"B\u00fcller","year":"2003","journal-title":"N Engl J Med"},{"issue":"11","key":"2020021109334868300_B18","doi-asserted-by":"crossref","first-page":"867","DOI":"10.7326\/0003-4819-140-11-200406010-00007","article-title":"Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial","volume":"140","author":"B\u00fcller","year":"2004","journal-title":"Ann Intern Med"},{"issue":"3","key":"2020021109334868300_B19","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s00415-014-7462-0","article-title":"Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis","volume":"262","author":"Caldeira","year":"2015","journal-title":"J Neurol"},{"issue":"18","key":"2020021109334868300_B20","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1212\/WNL.0000000000003886","article-title":"Outcome of intracerebral hemorrhage associated with different oral anticoagulants [published correction appears in Neurology. 2018;90(23):1084]","volume":"88","author":"Wilson","year":"2017","journal-title":"Neurology"},{"issue":"3","key":"2020021109334868300_B21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/jnnp-2017-316631","article-title":"Outcome of intracerebral haemorrhage related to non-vitamin K antagonists oral anticoagulants versus vitamin K antagonists: a comprehensive systematic review and meta-analysis","volume":"89","author":"Boulouis","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"2020021109334868300_B22","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1161\/STROKEAHA.116.015984","article-title":"Is there an obesity paradox for outcomes in atrial fibrillation? A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant trials","volume":"48","author":"Proietti","year":"2017","journal-title":"Stroke"},{"issue":"9734","key":"2020021109334868300_B23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(10)60835-5","article-title":"Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial","volume":"376","author":"Shakur","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"2020021109334868300_B24","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1055\/s-0036-1597296","article-title":"Laboratory assessment of direct oral anticoagulants","volume":"43","author":"Douxfils","year":"2017","journal-title":"Semin Thromb Hemost"},{"issue":"8","key":"2020021109334868300_B25","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/archinte.164.8.880","article-title":"The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage","volume":"164","author":"Rosand","year":"2004","journal-title":"Arch Intern Med"},{"issue":"6","key":"2020021109334868300_B26","first-page":"1145","article-title":"Questionable reversal of anticoagulation in the therapeutic management of cerebral haemorrhage associated with vitamin K antagonists","volume":"110","author":"Alonso de Leci\u00f1ana","year":"2013","journal-title":"Thromb Haemost"},{"issue":"7","key":"2020021109334868300_B27","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/STR.0000000000000069","article-title":"Guidelines for the management of spontaneous Intracerebral Hemorrhage: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"46","author":"Hemphill","year":"2015","journal-title":"Stroke"},{"issue":"2 suppl","key":"2020021109334868300_B28","doi-asserted-by":"crossref","first-page":"e601S","DOI":"10.1378\/chest.11-2302","article-title":"Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Lansberg","year":"2012","journal-title":"Chest"},{"issue":"2","key":"2020021109334868300_B29","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/STROKEAHA.116.014643","article-title":"Optimal timing of anticoagulant treatment after intracerebral hemorrhage in patients with atrial fibrillation","volume":"48","author":"Pennlert","year":"2017","journal-title":"Stroke"},{"issue":"4","key":"2020021109334868300_B30","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1001\/jamainternmed.2016.9369","article-title":"Outcomes associated with resuming warfarin treatment after hemorrhagic stroke or traumatic Intracranial hemorrhage in patients with atrial fibrillation","volume":"177","author":"Nielsen","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"10","key":"2020021109334868300_B31","doi-asserted-by":"crossref","first-page":"a1","DOI":"10.1055\/s-0034-1393172","article-title":"Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline","volume":"47","author":"Gralnek","year":"2015","journal-title":"Endoscopy"},{"issue":"9","key":"2020021109334868300_B32","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1111\/j.1572-0241.2007.01481.x","article-title":"Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis","volume":"102","author":"Garcia-Tsao","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"2020021109334868300_B33","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ajg.2011.480","article-title":"Management of patients with ulcer bleeding","volume":"107","author":"Laine","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"2020021109334868300_B34","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/ajg.2015.246","article-title":"ACG Clinical Guideline: diagnosis and management of small bowel bleeding","volume":"110","author":"Gerson","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"2020021109334868300_B35","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/ajg.2016.41","article-title":"ACG Clinical Guideline: management of patients with acute lower gastrointestinal bleeding [published correction appears in Am J Gastroenterol. 2016;111:755]","volume":"111","author":"Strate","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"2020021109334868300_B36","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1160\/TH16-07-0498","article-title":"Optimal timing of vitamin K antagonist resumption after upper gastrointestinal bleeding. A risk modelling analysis","volume":"117","author":"Majeed","year":"2017","journal-title":"Thromb Haemost"},{"issue":"6","key":"2020021109334868300_B37","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"issue":"4","key":"2020021109334868300_B38","first-page":"391","article-title":"Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis","volume":"166","author":"Dezee","year":"2006","journal-title":"Arch Intern Med"},{"issue":"1","key":"2020021109334868300_B39","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2141.2001.03070.x","article-title":"A comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarin","volume":"115","author":"Watson","year":"2001","journal-title":"Br J Haematol"},{"issue":"2","key":"2020021109334868300_B40","doi-asserted-by":"crossref","first-page":"e152S","DOI":"10.1378\/chest.11-2295","article-title":"Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Holbrook","year":"2012","journal-title":"Chest"},{"issue":"1 Suppl 1","key":"2020021109334868300_B41","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1111\/jth.12970","article-title":"New strategies for effective treatment of vitamin K antagonist-associated bleeding","volume":"13","author":"Yates","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"1 suppl 1","key":"2020021109334868300_B42","doi-asserted-by":"crossref","first-page":"65S","DOI":"10.1111\/j.1537-2995.2012.03663.x","article-title":"Adverse effects of plasma transfusion","volume":"52","author":"Pandey","year":"2012","journal-title":"Transfusion"},{"issue":"3","key":"2020021109334868300_B43","first-page":"149","article-title":"Prothrombin complex concentrates: an update","volume":"8","author":"Franchini","year":"2010","journal-title":"Blood Transfus"},{"issue":"6","key":"2020021109334868300_B44","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/j.1537-2995.2008.02080.x","article-title":"Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose","volume":"49","author":"Holland","year":"2009","journal-title":"Transfusion"},{"issue":"5","key":"2020021109334868300_B45","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1160\/TH16-04-0266","article-title":"Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis","volume":"116","author":"Chai-Adisaksopha","year":"2016","journal-title":"Thromb Haemost"},{"issue":"2","key":"2020021109334868300_B46","first-page":"93","article-title":"Use of protamine to rapidly reverse anticoagulant effect of unfractionated heparin in patients undergoing percutaneous coronary intervention","volume":"71","author":"Patel","year":"2007","journal-title":"Conn Med"},{"key":"2020021109334868300_B47","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/978-3-642-23056-1_11","article-title":"Neutralization of heparin activity","volume":"207","author":"Pai","year":"2012","journal-title":"Handb Exp Pharmacol"},{"issue":"7","key":"2020021109334868300_B48","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/MBC.0b013e3283494b3c","article-title":"Protamine reversal of low molecular weight heparin: clinically effective?","volume":"22","author":"van Veen","year":"2011","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"15","key":"2020021109334868300_B49","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood-2012-11-469130","article-title":"High incidence of antibodies to protamine and protamine\/heparin complexes in patients undergoing cardiopulmonary bypass","volume":"121","author":"Lee","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2020021109334868300_B50","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1111\/jth.13405","article-title":"Protamine (heparin)-induced thrombocytopenia: a review of the serological and clinical features associated with anti-protamine\/heparin antibodies","volume":"14","author":"Bakchoul","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2020021109334868300_B51","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/MBC.0b013e328201c9a9","article-title":"Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography","volume":"18","author":"Young","year":"2007","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"5","key":"2020021109334868300_B52","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1538-7836.2008.02933.x","article-title":"Recombinant human factor VIIa and a factor VIIa-analogue reduces heparin and low molecular weight heparin (LMWH)-induced bleeding in rats","volume":"6","author":"Lauritzen","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2020021109334868300_B53","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00277-003-0633-1","article-title":"Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin","volume":"82","author":"Ng","year":"2003","journal-title":"Ann Hematol"},{"issue":"4","key":"2020021109334868300_B54","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s11255-011-0104-x","article-title":"Dalteparin-associated catastrophic retroperitoneal hematoma successfully treated with recombinant factor VIIa","volume":"44","author":"Wang","year":"2012","journal-title":"Int Urol Nephrol"},{"issue":"9","key":"2020021109334868300_B55","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/j.1537-2995.2005.00548.x","article-title":"A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes","volume":"45","author":"MacLaren","year":"2005","journal-title":"Transfusion"},{"issue":"4","key":"2020021109334868300_B56","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.thromres.2011.10.037","article-title":"Fondaparinux - data on efficacy and safety in special situations","volume":"129","author":"Nagler","year":"2012","journal-title":"Thromb Res"},{"issue":"3","key":"2020021109334868300_B57","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1160\/TH12-08-0575","article-title":"Fondaparinux reversal with activated prothrombin complex concentrate in anesthetised bleeding rats","volume":"109","author":"Corbonnois","year":"2013","journal-title":"Thromb Haemost"},{"issue":"5","key":"2020021109334868300_B58","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.thromres.2008.07.007","article-title":"Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC","volume":"123","author":"Desmurs-Clavel","year":"2009","journal-title":"Thromb Res"},{"issue":"11","key":"2020021109334868300_B59","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1046\/j.1538-7836.2003.00536.x","article-title":"Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux","volume":"1","author":"Lisman","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"20","key":"2020021109334868300_B60","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1161\/01.CIR.0000038501.87442.02","article-title":"Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers","volume":"106","author":"Bijsterveld","year":"2002","journal-title":"Circulation"},{"issue":"2","key":"2020021109334868300_B61","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3109\/17482941.2011.567281","article-title":"Use of recombinant factor VIIa (NovoSeven(\u00ae)) in 8 patients with ongoing life-threatening bleeding treated with fondaparinux","volume":"13","author":"Luporsi","year":"2011","journal-title":"Acute Card Care"},{"issue":"10","key":"2020021109334868300_B62","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMra044440","article-title":"Direct thrombin inhibitors","volume":"353","author":"Di Nisio","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"2020021109334868300_B63","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1111\/jth.13117","article-title":"Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review","volume":"13","author":"Chai-Adisaksopha","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"14","key":"2020021109334868300_B64","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"key":"2020021109334868300_B65","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.thromres.2017.02.010","article-title":"Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study","volume":"152","author":"Schulman","year":"2017","journal-title":"Thromb Res"},{"issue":"5","key":"2020021109334868300_B66","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal - full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"issue":"15","key":"2020021109334868300_B67","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1182\/blood-2017-05-782060","article-title":"Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study","volume":"130","author":"Majeed","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2020021109334868300_B68","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1055\/s-0038-1636541","article-title":"Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: a prospective cohort study","volume":"118","author":"Schulman","year":"2018","journal-title":"Thromb Haemost"},{"key":"2020021109334868300_B69","volume-title":"Interim Report on the ANNEXA-4 Study: andexanet for reversal of anticoagulation in factor Xa - associated acute major bleeding","author":"Connolly"},{"issue":"S1","key":"2020021109334868300_B70","first-page":"PB449","article-title":"Reversal of direct factor Xa inhibitor-associated major bleeding with four-factor prothrombin complex concentrate: a systematic review and meta-analysis","volume":"2","author":"Piran","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"2020021109334868300_B71","unstructured":"UPMC System Pharmacy and Therapeutic Committee Formulary Review. Prothrombin complex concentrate (human) (Kcentra\u00ae, CSL Behring LLC). Available at: https:\/\/emcrit.org\/wp-content\/uploads\/2013\/12\/Kcentra_4FPCC_SPT.pdf. Accessed 20 December 2018."},{"key":"2020021109334868300_B72","article-title":"Andexanet alfa prescribing information","author":"Lexi-comp Drug Information Online"},{"key":"2020021109334868300_B73","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.thromres.2016.02.005","article-title":"Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events","volume":"140","author":"Majeed","year":"2016","journal-title":"Thromb Res"},{"issue":"2","key":"2020021109334868300_B74","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1182\/blood-2016-09-692996","article-title":"Emerging anticoagulant strategies","volume":"129","author":"Fredenburgh","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2020021109334868300_B75","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2020021109334868300_B76","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2020021109334868300_B77","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM199309023291001","article-title":"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction","volume":"329","author":"GUSTO investigators","year":"1993","journal-title":"N Engl J Med"},{"issue":"23","key":"2020021109334868300_B78","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/133\/5\/425\/1552091\/blood820746.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/133\/5\/425\/1552091\/blood820746.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T10:25:05Z","timestamp":1581416705000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/133\/5\/425\/272782\/Treatment-of-bleeding-complications-in-patients-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,31]]},"references-count":78,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,1,31]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2018-06-820746","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,31]]}}}